XOMA Royalty Corporation SEC Filings

XOMAP NASDAQ

Welcome to our dedicated page for XOMA Royalty Corporation SEC filings (Ticker: XOMAP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Royalty revenue can shift dramatically when a single milestone hits, and XOMA’s financials pack those shifts into dense footnotes and complex accounting tables. If you’ve ever scanned 10-Q line items searching for payable milestones or wondered whether an 8-K signals another portfolio acquisition, you know the challenge. Stock Titan gathers every disclosure the moment it hits EDGAR and converts pages of legal language into clear takeaways—no more hunting through PDFs.

Our platform covers the full range of filings, from the XOMA annual report 10-K simplified to each XOMA quarterly earnings report 10-Q filing. AI-powered summaries flag where royalty streams changed, tag cash-flow updates, and our expert analysis highlights what may impact valuation while keeping XOMA SEC filings explained simply. Need insider intel? Receive alerts on XOMA insider trading Form 4 transactions and track XOMA executive stock transactions Form 4 in real time. Governance questions are answered with one click to the latest XOMA proxy statement executive compensation, and sudden developments appear as XOMA 8-K material events explained.

With Stock Titan you get more than documents—you get answers. The dashboard lets you compare milestone revenue quarter over quarter, map portfolio diversification, and export data for modelling. Each note is cross-referenced so understanding XOMA SEC documents with AI becomes a two-click task. Investors rely on our XOMA earnings report filing analysis to project cash inflows, credit analysts monitor covenant triggers, and traders watch XOMA Form 4 insider transactions real-time to spot confidence signals. Whether you’re preparing diligence or simply need comprehensive coverage, Stock Titan delivers real-time updates and clarity.

07/29/2025 02:54 PM

Filing

[SCHEDULE 13G] XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock SEC Filing

Rhea-AI Summary

The Vanguard Group filed a Schedule 13G reporting that it crossed the 5 % ownership threshold in XOMA Royalty Corp (XOMAP). As of 30 Jun 2025, Vanguard beneficially owned 638,813 common shares, equal to 5.33 % of the class.

The position is largely passive. Vanguard holds 0 shares with sole voting power and 7,607 shares with shared voting power. It does, however, control disposition of most of the stake, with 628,533 shares under sole dispositive power and 10,280 under shared dispositive power. The firm files as an investment adviser (IA) and certifies the shares were acquired in the ordinary course of business, not to influence control.

While the disclosure does not imply activist intentions, the presence of a large institutional holder can enhance liquidity, broaden analyst coverage, and be viewed as a vote of confidence in XOMAP’s outlook.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What is the current stock price of XOMA Royalty Corporation (XOMAP)?

The current stock price of XOMA Royalty Corporation (XOMAP) is $25.7001 as of August 1, 2025.

What is the core business model of XOMA Royalty Corporation?

XOMA Royalty Corporation acquires future economic rights associated with licensed therapeutic candidates, providing non-dilutive, non-recourse funding to biotech and pharmaceutical companies. This model allows it to generate revenue through milestone payments and royalties without taking on traditional equity risks.

How does non-dilutive funding benefit biotech companies?

Non-dilutive funding allows companies to secure capital without issuing additional shares, thereby preserving existing ownership structures. This enables biotech firms to invest in research and development without the complications of equity dilution or increased financial liabilities.

What types of assets are included in XOMA Royalty Corporation's portfolio?

The portfolio encompasses a wide variety of licensed therapeutic candidates—ranging from early-stage investigational compounds to commercially approved drugs—across several key therapeutic areas such as antibody therapeutics, oncology, women’s health, and pediatric conditions.

How does the company generate revenue?

Revenue is generated from milestone payments and royalties associated with the progress and commercial success of the licensed therapeutic candidates. As these drugs achieve regulatory milestones or reach the market, the company receives corresponding payments based on the terms of the licensing agreements.

What makes XOMA Royalty Corporation different from traditional venture capital firms?

Unlike traditional venture capital, which typically provides equity funding at early stages, XOMA uses a royalty aggregation model that focuses on future cash flows. This model minimizes risk exposure related to company performance by aligning returns with the eventual success of licensed therapeutics.

How does XOMA manage the risks associated with early-stage drug development?

The company mitigates risks by diversifying its portfolio across multiple therapeutic areas and development stages. Detailed due diligence and a disciplined investment approach further help manage the uncertainties inherent in drug development.

What does 'royalty aggregation' mean in this context?

Royalty aggregation involves acquiring the rights to future royalties and milestone payments from licensed therapeutic candidates. This enables XOMA to build a predictable revenue stream based on the long-term commercial success of these assets.

How does XOMA support the long-term growth of its portfolio?

By acquiring a diversified range of royalty and milestone assets, XOMA positions itself to benefit from ongoing advancements in therapeutics. Its strategy of non-dilutive funding and rigorous portfolio management contributes to sustainable cash flow generation over time.